Fire Technology journal by Springer Nature

The aim of Fire Technology is to push forward the frontiers of knowledge and technology by encouraging interdisciplinary communication of significant technical developments in fire protection and subjects of scientific interest to the fire protection community at large. It is published in conjunction with the National Fire Protection Association (NFPA) and the Society of Fire Protection Engineers (SFPE). The mission of NFPA is to help save lives and reduce loss with information, knowledge, and passion. The mission of SFPE is advancing the science and practice of fire protection engineering internationally. Fire Technology publishes original contributions, both theoretical and empirical, that contribute to the solution of problems in fire safety science and engineering. It is the leading journal in the field, publishing applied research dealing with the full range of actual and potential fire hazards facing humans and the environment. It covers the entire domain of fire safety science and engineering problems relevant in industrial, operational, cultural, and environmental applications, including modeling, testing, detection, suppression, human behavior, wildfires, structures, and risk analysis. With thousands of subscribers worldwide, Fire Technology is a unique agent for the dissemination of scholarly work in fire safety science.

BioPharmX

BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. The Company is developing prescription products through its proprietary HyantX™ delivery system for dermatology indications. BioPharmX has two lead products in development, BPX-04 for the treatment of papulopustular rosacea and BPX-01 for the treatment of acne vulgaris.

Ravgen

Specializing in non-invasive prenatal genetic testing and paternity testing, Ravgen is focused on developing non-invasive prenatal diagnostic tests based on fetal DNA present in maternal blood. Diagnose single gene disorders, such as cystic fibrosis, sickle cell anemia and Downs syndrome, establish paternity and more early on in pregnancy.

Strain Genie

Strain Genie uses your DNA to help you find the right cannabis products. Our cannabis DNA test helps you find medical effectiveness and the perfect high. Get insights about your health and how cannabis can affect YOUR body with our proprietary cannabis-health-report. You have two choices: 1) If you've never had your DNA tested, order a DNA test kit from Strain Genie. We'll collect a saliva sample and process your report. 2) If you've already been tested (e.g. 23andMe or Ancestry.com), you can upload your raw data and we will process your report.

Prolexys Pharmaceuticals

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include a) solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) the colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. Prolexys' ability to identify and validate novel therapeutic targets is driven by its technological leadership in the field of proteomics and the application of proteomics technologies to its own, and its partners, drug discovery programs. Prolexys has developed two key technologies, a high throughput yeast 2 hybrid system called HyNet™, and a mass spectrometry-based protein science technology called HySpec™, that complement one another and provide a powerful approach for identifying novel molecular targets relevant to the treatment of human disease. In addition, Prolexys has developed HyScreen, to validate the therapeutic utility of these novel targets as well as in house high-throughput screening, in vivo pharmacology, medicinal chemistry, and drug development capabilities. Prolexys was formed in 2001 with investments from Myriad Genetics, Inc., Hitachi Ltd., Friedli Corporate Finance, A.G., and Oracle Corporation. The company is privately held and located in Salt Lake City, Utah.